Sodium ozagrel (
ozagrel), a selective
thromboxane A2 synthetase inhibitor, has been used for the treatment of various types of
acute ischemic stroke, except
cardioembolic stroke. Recently,
edaravone, a novel
free radical scavenger, has been approved for the treatment of
acute ischemic stroke within 24 hours after onset. Since these two drugs differ in mode of action, we hypothesized that combination of both drugs would yield further improvement of the outcome of patients with
acute ischemic stroke. The clinical efficacy of combination
therapy with
edaravone and
ozagrel for
acute ischemic stroke was studied retrospectively, and compared with that of
ozagrel alone. A total of 62 patients who suffered
acute ischemic stroke within 24 hours after onset during the 10-month period from June 2001 to March 2002, were treated with both
edaravone and
ozagrel (E-O group), while 76 patients during August 2000 to May 2001, were treated with
ozagrel alone (O group). The rate of modified Rankin Scale (MRS) 0 and 1 at discharge in the total
ischemic stroke and atherothrombotic
stroke, was significantly higher in the E-O group than in the O group. The improvement in MRS also differed between E-O group and O group in total. The difference was significant in patients with atherothrombotic
stroke but not in those with
lacunar stroke. These results indicate that combination
therapy with
edaravone and
ozagrel is more effective than mono-
therapy with
ozagrel for the treatment of acute ischemic, especially of atherothrombotic
stroke.